Compare Biogen Inc (BIIB) vs Altria Group Inc (MO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Altria Group Inc — how do they compare? Biogen Inc trades at $195.32 (market cap $28.34B), while Altria Group Inc trades at $71.12 (market cap $117.16B). The key difference: Altria Group Inc is far larger — about 4.1× Biogen Inc's market cap, and Altria Group Inc pays a 6.04% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | MO | |
|---|---|---|
Market Cap | $28.34B | $117.16B |
Sector | Health | Consumer Staples |
52-Week High | $216.63 | $74.55 |
52-Week Low | $122.68 | $54.72 |
Enterprise Value | $30.62B | $138.23B |
Dividend Yield | — | 6.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
MO trades at $71.87, up 0.14% today, with a neutral technical signal and bullish moving averages. The company reported a net income margin of 39.52% for 2025, with recent earnings beating expectations in Q1 2026. Strong cash flow from operations of $9.29B supports its dividend, with a recent $1.06 payment declared. Analyst consensus is bullish with a $71.00 price target.
Outlook remains stable with defensive qualities highlighted by media, but risks include high debt levels and regulatory pressures. The stock offers a high yield and pricing power, though revenue trends show slight volatility. Investment appeal centers on dividend sustainability and cash flow generation amid a challenging industry backdrop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
